+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis



Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis



Blood 91(9): 3347-3356



Two major isoforms of PML-RARalpha are associated with (15;17)-positive acute promyelocytic leukemia (APL); however, functional differences between these isoforms have been difficult to define, and the molecular mechanism by which each isoform contributes to the pathogenesis of APL is not fully understood. To address these issues, the 'short' (S) and 'long' (L) isoforms of PML-RARalpha were constitutively expressed in the factor-dependent human erythroleukemia cell line, TF1. Expression of the L, but not the S, isoform inhibited growth of these cells in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF). In the absence of GM-CSF, the S isoform partially protected against apoptosis, while the L isoform accelerated cell death. Treatment with all-trans retinoic acid (ATRA) inhibited cell growth and caused apoptosis only in PML-RARalpha-expressing cells, and these effects of ATRA were more marked in cells expressing the L isoform. ATRA treatment also led to downregulation of bcl-2 and endogenous RARalpha in PML-RARalpha-expressing cells, but had little effect on the level of exogenously expressed PML-RARalpha. We conclude that (1) subtle differences exist in the biologic activities of the L and S isoforms of PML-RARalpha, and (2) both isoforms are capable of transducing an ATRA-mediated signal that leads to downregulation of bcl-2 and induction of programmed cell death.

(PDF emailed within 1 workday: $29.90)

Accession: 008378502

Download citation: RISBibTeXText

PMID: 9558392


Related references

Distinct Gene Expression Profiles Underlying Trichostatin A and All-Trans-Retinoic Acid - Induced Growth Inhibiton of PML-RARalpha and PLZF-RARalpha Acute Promyelocytic Leukemia Cells. Blood 100(11): Abstract No 2207, November 16, 2002

Retinoic acid, interferons and tumor necrosis factor-alpha increase PML/RARalpha gene expression in NB4 promyelocytic leukemia cells. British Journal of Haematology 102(1): 168, July 1, 1998

Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha. Blood 97(10): 3234-3243, 2001

Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all-trans retinoic acid in acute promyelocytic leukemia cells. Cancer Research 58(24): 5770-5776, 1998

Constitutive degradation of the PML/RARalpha protein is present in retinoic acid -resistant acute promyelocytic leukemia cells and involves the proteasome proteolytic pathway. Blood 90(10 SUPPL 1 PART 1): 70A, Nov 15, 1997

Removal of the dominant negative PML-RARalpha protein and upregulation of C/EBPepsilon expression are necessary for all trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 98(11 Part 1): 306a, November 16, 2001

Constitutive expression of cellular retinoic acid binding protein II in acute promyelocytic leukemia cells. Proceedings of the American Association for Cancer Research Annual Meeting 39: 106, March, 1998

Retinoic acid-induced expression of apolipoprotein D and concomitant growth arrest in human breast cancer cells are mediated through a retinoic acid receptor RARalpha-dependent signaling pathway. Journal of Biological Chemistry 271(50): 32105-32111, 1996

Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia. Leukemia 11(11): 1950-1956, 1997

Effects of retinoic acid on oncogene expression and clonogenic growth of human myeloid leukemia cells. Clinical Research 34(1): 40A, 1986

Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood 94(2): 793-802, 1999

Different kinetics of WT1 and PML-RARalpha gene expression levels during remission induction therapy with all-trans retinoic acid alone in acute promyelocytic leukemia. International Journal of Hematology 84(5): 468-470, 2006

In vitro inhibition of promyelocytic leukemia/retinoic acid receptor-alpha (PML/RARalpha) expression and leukemogenic activity by DNA/LNA chimeric antisense oligos. Oncology Research 16(3): 157-166, 2006

Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84(11): 3843-3849, 1994

Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid. Cancer Research 61(14): 5468-5473, 2001